Virios Therapeutics, Inc. Stock Price, News & Analysis

Welcome to our dedicated page for Virios Therapeutics news (Ticker: VIRI), a resource for investors and traders seeking the latest updates and insights on Virios Therapeutics stock.

The VIRI news archive on Stock Titan provides historical coverage of Virios Therapeutics, Inc., a development-stage biotechnology company that focused on antiviral combination therapies for conditions such as fibromyalgia and Long-COVID. Company press releases repeatedly describe Virios Therapeutics’ strategy of combining antiviral agents with celecoxib to suppress herpesvirus replication and address diseases associated with a viral-triggered abnormal immune response.

Readers can review news items detailing clinical and corporate milestones. These include updates on the IMC-2 Long-COVID program, such as the Bateman Horne Center’s randomized, double-blind, placebo-controlled Phase 2a study and earlier exploratory work reporting reductions in fatigue, orthostatic intolerance, pain and anxiety with the valacyclovir and celecoxib combination. News releases also discuss the development status of IMC-1, a fixed-dosage combination of famciclovir and celecoxib that has received FDA Fast Track designation for fibromyalgia.

The archive further documents financing activities, including public offerings intended to support planned Long-COVID studies, as well as patent developments like the publication of a global patent application covering IMC-2 for Alzheimer’s and COVID-19. A key set of news items covers the announced business Combination between Virios Therapeutics and Wex Pharmaceuticals, Inc., the adoption of the Dogwood Therapeutics, Inc. name, and the transition of trading from the VIRI ticker to DWTX on the Nasdaq Capital Market.

By browsing these historical news releases, investors and researchers can trace how Virios Therapeutics’ antiviral programs evolved and how they were integrated into the broader Dogwood Therapeutics pipeline. This context can be useful for understanding the scientific and corporate background behind the current Dogwood Therapeutics, Inc. disclosures.